DPHARMA: Duopharma Biotech Berhad - Summary | Jitta

Duopharma Biotech Berhad

MAL:DPHARMA

Price
RM1.31
Loss Chance
42.9%
6.53JITTA SCORE
2.60%Over Jitta Line
Jitta Ranking
40 / 994
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (70)
Recent Business Performance (91)
Financial Strength (78)
Return to Shareholders (45)
Competitive Advantage (66)
Jitta Signs
Revenue and EarningConsistent
Recent Business PerformanceEarning Growth Last Year
Dividend PayoutIncreasing Every Year
Interest Coverage RatioVery Good
SG&A to SalesDecreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
6.53
2.60%
5.34
133.98%
3.71
132.79%
Pharmaceuticals
5.14
106.87%
3.28
500.97%
6.58
33.51%
COMPANY DESCRIPTION
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products, such as vitamins, minerals, and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, including diabetes, cancer, cardiovascular, renal, and other diseases. The company’s product portfolio includes covasc, crystorvas, and vytocor; lebreta, and krabeva; and unihepa, erysaa, bi-haemosol, and haemosol. In addition, it offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, IRORO Nutreatment, and Uphamol brands. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is based in Klang, Malaysia.